GLENMARK

targets a $480 million US opportunity through pain and allergy segment launches. Milnacipran offers niche demand, while fluticasone taps a larger OTC market. The strategy strengthens Glenmark's US portfolio, balancing prescription and consumer healthcare, driven by scale, pricing power, and limited competition.